Orsola Botti

Ms. Orsola Botti

Eurofins (Ireland), Dublin, Ireland
+2
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
MCMarina Cerqua
Marina Cerqua
Orsola BottiOrsola Botti
Orsola Botti
MAMaddalena Arigoni
Maddalena Arigoni
NGNoemi Gioelli
Noemi Gioelli
Guido SeriniGuido Serini
Guido Serini
DADogus Murat Altintas
Dogus Murat Altintas
MET is an oncogene encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF). Upon ligand binding, MET activates multiple signal transducers, including PI3K/AKT, STAT3, and MAPK. When mutated or amplified, MET becomes a “driver” for the onset and progression of cancer. The most frequent mutations in the MET gene affect the splicing sites of exon 14, leading to the deletion of the receptor’s juxtamembrane domain (MET∆14). It is currently believed that, as in gene amplification, MET∆14 kinase is constitutively active. Our analysis of MET in carcinoma cell lines showed that MET∆14 strictly depends on HGF for kinase activation. Compared with wt MET, ∆14 is sensitive to lower HGF concentrations, with more sustained kinase response. Using three different models, we have demonstrated that MET∆14 activation leads to robust phosphorylation of AKT, leading to a distinctive transcriptomic signature. Functional studies revealed that ∆14 activation is predominantly responsible for enhanced protection from apoptosis and cellular migration. Thus, the unique HGF-dependent ∆14 oncogenic activity suggests consideration of HGF in the tumour microenvironment to select patients for clinical trials.

22 August 2021 in Cancer Reports
Verified
Journal Article
Open access
PDF file
JTJoonas Terävä
Joonas Terävä
AVAlejandra Verhassel
Alejandra Verhassel
Orsola BottiOrsola Botti
Orsola Botti
KIKhirul Islam
Khirul Islam
JLJanne Leivo
Janne Leivo
KGKamlesh Gidwani
Kamlesh Gidwani
Background: Breast cancer is a very common cancer that can be severe if not discovered early. The current tools to detect breast cancer need improvement. Cancer has a universal tendency to affect glycosylation. The glycosylation of circulating extracellular vesicle‐associated glycoproteins, and mucins may offer targets for detection methods and have been only explored in a limited capacity.Aim: Our aim was to develop an approach to detect the aberrant glycosylation of mucins and extracellular vesicle‐associated glycoproteins from human sera using fluorescent nanoparticles, and preliminarily evaluate this approach for the differential diagnosis of breast cancer.Methods and results: The assay involved immobilizing glycosylated antigens using monoclonal antibodies and then probing their glycosylation by using lectins and glycan‐specific antibodies coated on Eu+3‐doped nanoparticles. Detection of mucin 1 and mucin 16 glycosylation with wheat germ agglutinin, and detection of the extracellular vesicle‐associated CD63 were found to have better diagnostic ability for localized breast cancer than the conventional assays for mucin 1 and mucin 16 based tumor markers when the receiver operating characteristics were compared.Conclusions: These results indicate that successful differential diagnosis of primary breast cancer may be aided by detecting cancer‐associated glycosylation of mucin 1 and mucin 16, and total concentration of CD63, in human serum.

Verified
Journal Article
Open access
PDF file
DADogus Murat Altintas
Dogus Murat Altintas
SGSimona Gallo
Simona Gallo
CBCristina Basilico
Cristina Basilico
MCMarina Cerqua
Marina Cerqua
ABAlessio Bocedi
Alessio Bocedi
PCPaolo m Comoglio
Paolo m Comoglio
The tyrosine kinase receptor encoded by the MET oncogene has been extensively studied. Surprisingly, one extracellular domain, PSI, evolutionary conserved between plexins, semaphorins, and integrins, has no established function. The MET PSI sequence contains two CXXC motifs, usually found in protein disulfide isomerases (PDI). Using a scrambled oxidized RNAse enzymatic activity assay in vitro, we show, for the first time, that the MET extracellular domain displays disulfide isomerase activity, abolished by PSI domain antibodies. PSI domain deletion or mutations of CXXC sites to AXXA or SXXS result in a significant impairment of the cleavage of the MET 175 kDa precursor protein, abolishing the maturation of α and β chains, of, respectively, 50 kDa and 145 kDa, disulfide-linked. The uncleaved precursor is stuck in the Golgi apparatus and, interestingly, is constitutively phosphorylated. However, no signal transduction is observed as measured by AKT and MAPK phosphorylation. Consequently, biological responses to the MET ligand—hepatocyte growth factor (HGF)—such as growth and epithelial to mesenchymal transition, are hampered. These data show that the MET PSI domain is functional and is required for the maturation, surface expression, and biological functions of the MET oncogenic protein.